Nkarta, Inc. (NKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.73+13.07%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NKTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
NKTX — earnings miss
Dated 2026-08-10
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the “Securities Act”), unless the Company specifically states that the information is to be considered “filed” under the Exchange Act…
Why it matters: Nkarta reported $243.2 million in cash and investments at June 30. A shorter runway could force a change to trial plans.
Worry ifA company update cuts its cash runway from into 2029, or reports less than $200 million in cash and investments.
Less concerning ifA later update keeps the runway into 2029 and reports cash and investments at or above $243 million.
Why it matters: Q2 costs and losses rose from Q1. Another increase would add pressure to the cash runway.
Worry ifIn the Q3 report, total operating expenses top $43.1 million or net loss tops $40.4 million.
Less concerning ifIn the Q3 report, total operating expenses are $43.1 million or less, and net loss is $40.4 million or less.
Why it matters: Outpatient dosing may let more patients get care near home. It also tests whether the trials can run beyond major centers.
Supportive ifThe next update says both trials dose patients at community sites. Enrollment continues at 4 billion cells per dose.
Worry ifA trial update says outpatient dosing has stopped or enrollment at the 4 billion-cell dose has paused.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$269 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $708 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,858 loss on $10,000 · 58.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.